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Background: Genomic tumor information, such as identification of amplified oncogenes, can be used to plan treatment.
The two sources of a brain tumor that are commonly available include formalin-fixed, paraffin-embedded (FFPE) sections
from the small diagnostic biopsy and the ultrasonic surgical aspiration that contains the bulk of the tumor. In research
centers, frozen tissue of a brain tumor may also be available. This study compared ultrasonic surgical aspiration and FFPE
specimens from the same brain tumors for retrieval of DNA and molecular assessment of amplified oncogenes.
Methods: Surgical aspirations were centrifuged to separate erythrocytes from the tumor cells that predominantly formed
large, overlying buffy coats. These were sampled to harvest nuclear pellets for DNA purification. Four glioblastomas, 2
lung carcinoma metastases, and an ependymoma were tested. An inexpensive PCR technique, multiplex ligation-
dependent probe amplification (MLPA), quantified 79 oncogenes using 3 kits. Copy number (CN) results were normalized
to DNA from non-neoplastic brain (NB) in calculated ratios, [tumor DNA]/[NB DNA]. Bland-Altman and Spearman rank
correlative comparisons were determined. Regression analysis identified outliers.
Results: Purification of DNA from ultrasonic surgical aspirations was rapid (<3 days) versus FFPE (weeks) and yielded
greater amounts in 6 of 7 tumors. Gene amplifications up to 15-fold corresponded closely between ultrasonic aspiration
and FFPE assays in Bland-Altman analysis. Correlation coefficients ranged from 0.71 to 0.99 using 3 kit assays per tumor.
Although normalized CN ratios greater than 2.0 were more numerous in FFPE specimens, some were found only in the
ultrasonic surgical aspirations, consistent with tumor heterogeneity. Additionally, CN ratios revealed 9 high-level (≥ 6.0)
gene amplifications in FFPE of which 8 were also detected in the ultrasonic aspirations at increased levels. The ultrasonic
aspiration levels of these amplified genes were also greater than 6.0 CN ratio, except in one case (3.53 CN ratio). Ten of 17
mid-level (≥3.0 & <6.0 CN ratio) amplifications detected in FFPE were also detected as being increased (≥ 2.0 CN ratio) in
the aspirations.
Conclusions: Buffy coats of centrifuged ultrasonic aspirations contained abundant tumor cells whose DNA permitted
rapid, multiplex detection of high-level oncogene amplifications that were confirmed in FFPE.
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Oncogenes encode proteins that promote tumor growth,
survival under adverse conditions, and invasion. Many
studies have detected amplified oncogenes in high grade
brain tumors, especially glioblastoma or glioblastoma mul-
tiforme (GBM). Therefore, assays to identify amplified
genes are proposed to become critical in patient care as
monoclonal antibodies and small molecules that inhibit
proteins encoded by oncogenes become available. Identifi-
cation of amplified genes in a rapid, multiplex manner is
relevant for stratifying patients to clinical trials and treat-
ments. Brain tumor specimens for molecular studies
include ultrasonic surgical aspirations available at the time
of surgery and small, diagnostic biopsies that are pro-
cessed as formalin-fixed, paraffin-embedded (FFPE)
samples. Sometimes tumor fragments are resected and are
also processed as FFPE samples. Although tissue frozen
for storage at the time of surgery can also be released for
DNA studies, it is not usually available outside of research
settings. Ultrasonic surgical aspirations are not routinely
used for diagnostic purposes and represent an untapped
source of abundant, fresh tumor DNA. With laboratory
support for processing cellular fluids and the expertise for
confirming tumor cell content morphologically, pathology
departments are well suited for providing cellular or nu-
clear pellets from ultrasonic surgical aspirations to provide
tumor DNA needed in molecular testing. Surgical aspira-
tions can quickly provide DNA to speed up turnaround
times and produce higher yields than FFPE sections of
small biopsies.
Brain tumors debulked by ultrasonic surgical aspiration
yield suspensions of single cells, minute tissue fragments,
and blood in saline. Following introduction of this tech-
nique in the 1970’s, ultrasonic aspiration became routine
in microneurosurgery [1]. Unlike the characteristically
small diagnostic biopsies of brain tumors, ultrasonic surgi-
cal aspirations contain ample tumor cells in large volumes
of fluid. The ultrasonic apparatus consists of a computer-
ized control unit with settings for different amplitudes of
ultrasonic waves and speeds of irrigation and aspiration.
Tumor tissues are targeted and selectively aspirated. An
advantage of the ultrasonic aspiration technique over tis-
sue dissection is the reduced need for retraction of normal
brain in the patient. Accordingly, the use of ultrasonic sur-
gical aspiration to debulk intracranial tumors is common
and explains the unfortunate paradox of having only small
diagnostic tissue biopsies from large brain tumors avail-
able for molecular studies outside of research settings. Al-
though ultrasonic aspiration specimens have yielded viable
tumor cells for experimental studies [2-4], their lack of tis-
sue architecture greatly diminishes their usefulness in
diagnostic pathology. For example, regions of tumor ne-
crosis that are a useful diagnostic feature in high grade
tumors are prone to disintegrate during the aspirationprocedure. Although some institutions preserve small por-
tions of ultrasonic aspirations in FFPE blocks, the intact
tissue fragments from biopsies are preferred and routinely
relied upon for diagnostic evaluation of primary and meta-
static brain tumors. Ultrasonic surgical aspirations, that
contain the bulk of brain tumor tissue in a dispersed and
disaggregated form, seldom provide the complete architec-
tural features of the tumors that aid in determining
morphologic diagnoses.
In this study, ultrasonic aspirations of brain tumors were
tested to see if they would yield tumor DNA that is appro-
priate for studies to detect amplified oncogenes. Testing
methods that identify amplified genes as potential treat-
ment targets in individual tumors would ideally be
performed as soon after surgery as possible. The genes
tested with commercial MLPA kits are known to be ampli-
fied in association with malignancy. The amounts of DNA
purified from ultrasonic aspirations of GBMs were found
to be especially ample. These DNA samples were analyzed
for amplifications in seventy-nine oncogenes, with results
compared to those from FFPE-derived DNA and with
fluorescence in situ hybridizaiton (FISH) results for EGFR
gene amplification in FFPE tissue sections. The MLPA
assays on ultrasonic aspirations identified high-level amp-
lified genes within a few days at low cost and served as a
preview of the more sensitive FFPE assay results that be-
came available later.
Methods
Patient Population, Specimen Retrieval and DNA
Purification
Permission from our Institutional Review Board was
obtained for retrieval and study of the excess amounts of
ultrasonic aspiration and FFPE specimens taken from
brain tumors resected in 2008–2009 in a pilot study of
using these specimens for molecular tests. Ultrasonic
aspirations from seven brain tumors, including four glio-
blastomas (GBM1-4), two lung carcinomas metastases
(LCM1-2) and an ependymoma (EP1), were tested. The
patients (all male except for one female with a GBM)
were 44 to 81 yrs of age. Samples were obtained in saline
with a Cavitron Ultrasonic Aspirator Excel (Valleylab-
Tyco International, Boulder, CO) set at 23 to 36 MHz.
The volume (cc) of each tumor present preoperatively
and postoperatively was estimated by the neurosurgeon.
The ultrasonic surgical aspirations were not designated
to be used for any diagnostic purpose. The specimens in
this study were delivered to the laboratory within 24 hr
of surgical resection, either fresh or after overnight re-
frigeration. Portions of ultrasonic aspiration specimens,
15 to 30 ml, were centrifuged at 500 g for 10 min.
Tumor cells sedimented as large buffy coats above the
erythrocytes and beneath floating necrotic debris.
According to the manufacturer’s recommendations
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coat were pipetted and combined with purification kit
components to obtain a nuclear pellet that was pro-
cessed immediately or frozen for later purification. All
specimens yielded measureable amounts of DNA. For
comparisons in each tumor, DNA from routine FFPE
sections (10 μm thick, 10 per tumor) was purified with a
Qiagen FFPE DNA purification kit. In each case tumor
cells represented at least 90% of nucleated cells in the
tissue sections. Proteinase K digestions at 55°C were
extended as needed to achieve digestion of the tissues.
Purified DNA was evaluated and quantified with spec-
trometry using absorbance measurements at 260 and
280 nm (JENWAY Genova, Jenway Limited, Essex,
England).
Histological Review of Tumor Specimens
Diagnostic FFPE tissue sections, available from all
tumors, were reviewed microscopically to characterize
the pathological features. Portions of ultrasonic aspir-
ation specimens that had also been processed as FFPE
specimens were available. Hematoxylin and eosin stained
FFPE sections were evaluated. The number of mitotic
figures in ten high power fields (HPFs) (400X magnifica-
tion) was determined for each tumor in duplicate
counts. Also, stains for Ki67 reactive cells were per-
formed at the time of diagnosis for some tumors using a
pre-diluted antiKi67 antibody (Ventana Medical Sys-
tems, Oro Valley, AZ) for direct staining on an auto-
mated immunohistochemical stainer (Benchmark XT,
Ventana Medical Systems). Pre-diluted, non-reactive
mouse monoclonal negative control (Ventana) solutions
were applied to separate tissue sections. The percentages
of tumor cells positive for Ki67 specific staining were
determined with an automated cellular imaging system
(Chromavision ACIS, San Juan Capistrano, CA) with
verification by manual counts at the time of review. If
interference from background staining was present,
manual counts were substituted.
EGFR FISH
Inclusion of probe sets for EGFR in the MLPA kits per-
mitted comparison of MLPA and FISH copy number
(CN) data for this gene in each tumor. FISH probes for
a control locus, 7p11.1-q11.1, D7Z1, and the EGFR band
region, 7p11.2-7p12, (Vysis Locus Specific Identifier
(LSI) EGFR SpectrumOrange/CEP 7 SpectrumGreen,
Abbott Molecular Inc., Des Plaines, IL) were hybridized
to interphase nuclei. Paraffin sections of all tumors and
cytologic smears prepared from some of the ultrasonic
aspiration specimens were examined. Smears from
aspirations were fixed, denatured, and hybridized with
probes overnight. Un-hybridized probes were washed
away. Diamino-phenylindole (DAP1) fluorescent blue(Abbott Molecular) stained the nuclei. Slides were
scanned on a fluorescent microscope (Leica DMR, Wet-
zlar, GM) for analysis with images captured using a
digital camera (Applied Imaging, San Jose, CA) and
CytoVision v4.02 imaging software (Applied Imaging).
Sections from FFPE tissue were cut at a thickness of five
microns, deparaffinized (Paraffin Pretreatment Reagent
Kit II, Abbott Molecular), processed on a VP2000 Pro-
cessor (Abbott Molecular) and then FISH probes for
EGFR and CEP 7 were applied and analyzed as described
above. Amplifications of EGFR were observed as average
EGFR to CEP 7 signal ratios greater than two for at least
20 cells (usually many more). The results were deter-
mined by averages of all cells that could be evaluated.
Proteinaceous debris hindered FISH interpretations in
some of the ultrasonic surgical aspiration specimens.
Ratios of total EGFR and CEP 7 signals per tumor, indi-
vidual EGFR/CEP 7 signals per cell and medians of the
signal ratios per cell were described.
MLPA
The PCR-based technique, MLPA, involved multiple
steps, including exposure of DNA to gene-specific probe
sets, enzymatic ligation, PCR, and capillary electrophor-
esis (CE) to separate PCR products. Briefly, as explained
earlier [5], 200 μg of DNA from each tumor sample and
normal brain in buffer were denatured at 98°C for
30 min in a thermocycler (MasterCycler personal
Eppendorf, Hamburg, GM) and were then hybridized to
MLPA probes (SALSA P171, P172 and P173 kits, MRC-
Holland, The Netherlands) according to kit instructions.
The manufacturer selected genes according to literature
documenting amplification in tumors. In addition to
gene specific sequences, the probes also contained
universal PCR primers, X and Y, and stuffer sequences
for subsequent identification of specific gene amplicons
by size using CE. Ligase65 (MRC-Holland) generated
ligations specific for perfectly hybridized probe pairs
(sets) at ligation junctions in the DNA and the enzyme
was then heat inactivated. Ligated probes were PCR
amplified with polymerase (MRC-Holland) according to
instructions. PCR products were separated on a CEQ
8000 (Beckman-Coulter, Fullerton, CA) and were then
identified according to the length of amplicons.
Fragment analysis of PCR products produced a series
of linear peaks (signals of fluorescence) corresponding to
the relative quantities of PCR products that were pro-
portional to initial amounts of DNA (or CN) of the tar-
geted genes. Slightly less efficient amplifications of
longer amplicons accounted for minor reductions in
their peak heights. All of the genes tested in the three
MLPA kits, P171, P172, and P173, are listed as follows:
AKT1, AURKA, BCAR2, BCAS1-2, BCL2, BCL2A1,
BCL2L1, 11 and 13, BCL6, BCLG, BIRC1-5, BRAF,
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CENPF, CYP27B1, EGFR, EMS1, ERBB2 and 4, ESR1,
EVI1, FGF3 and 4, FGFR1, FLJ20517, GNAS, GSTP1,
HMGA1, IGF1R, IGFBP2,4 and 5, IRS2, JAK2, MDM2
and 4, MET, MMP7, MOS, MYCL1, MYBL1 and 2,
MYC, MYCN, NFKBIE, NRAS, NTRK1-3, PDGFRA and
B, PIK3C2B, PIK3CA, PPM1D, PSMB4, PTK2, PTP4A3,
PTPN1, RELA, RNF139, RUNX1, SERBINB2, 7 and 9,
TERT and TOM1L2.
Occasional failures to see peaks in one of the eight ca-
pillary tubes during a CE run were attributed to low
current whenever the peak was obtained after repeating
CE. Successful concurrent results for NB were required
for a CE run of tumor samples to be further analyzed.
Normalization of CN
For detection of somatic changes found in highly malig-
nant tissues, there were no known reference probes that
could be relied on to maintain their normal CN at the
time of this study. Large numbers of genes are lost or
amplified in malignant tumors leading to considerable
variability in the CN of individual tumors. Also, genetic
variations and mutations in tumors, such as nucleotide
deletions, insertions, or substitutions near the ligation
junctions could potentially impact ligation efficiency. In
this study the result of each probe set in each tumor
specimen was normalized with CN for the same probe
set in DNA from non-neoplastic brain (NB) assayed
concurrently. Comparisons of all tumors with the same
source of NB controlled for assay to assay variation. Ali-
quots of NB were from an 82 year old woman’s normal
occipital lobe (Biochain, Hayward, CA).
The CN ratios, or fold-differences from normal for
each gene, are represented by the ratio, [tumor DNA] /
[NB DNA], derived from measurements of the CE peaks.
The CN ratio was calculated after peaks of non-
amplified genes on CE graphs, representing relative
amounts of DNA, were matched with the average of two
NB samples analyzed in the same assay run. Peak
heights of non-amplified genes in tumor samples and
NB were adjusted to approximately the same scale as
graphical printouts from CE were produced. Final, finer
adjustments were made in spreadsheets by maximizing
alignments of trendlines for non-amplified genes. Scat-
terplots were evaluated to check the reactions of NB
DNA with the MLPA probes compared to expected
values provided by the manufacturer. Overlays of NB
results obtained in GBM1’s assays of FFPE, using P171,
P172, and P173 kits, with graphs of normal values pro-
vided in the MLPA kits’ literature, demonstrated com-
parable overall detection of the two populations of
normal DNA data points (Figure 1).
Regression analysis of NB’s scatterplots demonstrated
that results obtained using one of the two probe sets forERBB4 was an outlier. In P171 data points, ERBB4’s
probe set result was at the 95% confidence limit for the
overall NB sample population. All other probe set results
fell above the lower 95% confidence limit for the NB
sample. Also, three probe sets were slightly out of range
in the opposite direction so that missing a low level
amplification was a concern but other probe sets for
these genes were within the 95% confidence limits so
that missing a significant CN gain after their results were
averaged would be unlikely. The probe sets with results
above the confidence limits included 1 of 2 for IGFBP2,
1 of 2 for NTRK1, and 1 of 4 for IGF1R.
The normal CN range was set at ≥ 0.75 to ≤ 1.50, with
CN ratios ≥ 2.0 considered to be amplified. High-level
gene amplifications in glioblastomas have been previ-
ously set at 6-fold greater than diploid or 12 or more
copies per nucleus [6]. In this study CN ratios ≥ 6.0 were
also designated as high-level amplifications and lesser
amplifications were set at CN ratios of ≥ 3.0 and< 6.0
for mid-level and ≥ 2.0 and< 3.0 for low-level amplifica-
tions. Averaged results for two replicates of amplified
and non-amplified genes in ultrasonic aspiration tumor
DNA were compared to results for two replicates of
genes in NB for each gene’s probe set (or ligated pair).
Results for multiple probe sets for a gene were averaged.
MLPA analysis using the kits, P171, P172, and P173, was
performed on FFPE DNA in two replicates from each of
7 tumors in 15 of the 21 assays and in single replicates
in 6 due to DNA depletion from the small specimens.
Statistical methods and correction factors
Excel was used to prepare graphs for images, determine
Spearman rank correlation coefficients, regression ana-
lysis, etc. Outlier identification was performed with re-
gression analysis to detect data points at or beyond 95%
confidence intervals for residuals. A Bland-Altman plot
to compare MLPA results of cavitronic ultrasonic surgi-
cal aspiration and FFPE assays was generated with R,
version 2.10 (The R Foundation for Statistical Comput-
ing, http//www.R-project.org), statistical software.
Results
DNA purification yields
Successful DNA purification was achieved for all of the
tumors. The greatest yields of DNA (43.0 to 77 μg) were
obtained from buffy coats of glioblastoma ultrasonic as-
piration specimens. The FFPE sections from all of the
tumors yielded less DNA (6.4 to 20.5 μg) as seen in
Table 1.
Clinicopathologic features of the tumors
Features of the tumors were typical for their diagnostic
classification as glioblastomas, metastatic tumors, and an
ependymoma. Photomicrographs of the ultrasonic surgical
Figure 1 Scatterplots of DNA values for genes in non-neoplastic brain versus normal values provided in MLPA kits. The amounts of
DNA represent copy number (CN) for each gene assayed. The non-neoplastic (or normal) brain DNA (NB) was evaluated by comparing its values
with expected values provided by the manufacturer. Regression analysis of NB values, that were obtained when FFPE-GBM1 was tested with the
P171 kit, identified ERBB4 at the lower limit of the 95 % confidence interval as an outlier. The overlays of observed NB values with normal values
included in the P171, P172, and P173 kits demonstrated overall correspondence for both sources of non-neoplastic DNA in the data distributions.
Their trendlines are also shown.
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Table 1 DNA data according to sample type, cavitronic










GBM1 CUSA 1.38 49.1
FFPE 1.98 6.7
GBM2 CUSA 1.84 77.0
FFPE 1.98 7.9
GBM3 CUSA 1.84 43.3
FFPE 1.86 6.4
GBM4 CUSA 1.67 44.6
FFPE 1.90 7.0
LCM1 CUSA 1.85 17.9
FFPE 1.81 11.3
LCM2 CUSA 1.16 14.6
FFPE 1.63 20.5
EP1 CUSA 1.88 12.1
FFPE 1.55 10.1
GBM=glioblastoma, LCM= Lung carcinoma metastasis, EP1 = Ependymoma.
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tions (400X magnification) illustrates the similarity of
tumor cells in the two types of specimens (Figure 2).
There were too few cases to evaluate whether characteris-
tic morphologic profiles for amplified gene(s) in these
tumors were present. Mitotic figures among the glioblast-
omas were most numerous in GBM1 and mitoses among
all tumors were most numerous in LCM2 (Table 2).
EGFR FISH
Analysis of EGFR with FISH was used to correlate with
MLPA assay results. Signals were counted in the FFPE sec-
tions. The CN for EGFR was increased in the four glio-
blastomas with ratios of EGFR to CEP 7 increased to
values of more than 20 in at least some cells of each glio-
blastoma. In the metastatic tumors averages of CNs for
EGFR were 2.5 to 2.8 per cell with EGFR to CEP 7 ratios
remaining below 2.0. Distributions of the EGFR/CEP 7
ratios are shown in Figure 3A and illustrate “tailing off” in
the data towards high-level amplifications in individual
cells. Representative cells with amplified EGFR from the
glioblastomas and from one of the metastases lacking
amplification are shown in Figure 3B. The EGFR/CEP 7
ratios are listed for all tumors in Table 3. The CN of CEP
7 varied and was increased (averages of 2.7 to 3.8) in glio-
blastomas. The CN of CEP 7 varied in LCM1 and LCM2
with averages of 2.5 and 2.6, respectively.
MLPA molecular results
Productive CE runs were obtained for all tumors. Prior
to normalization of tumor CN, the output of CE datafrom all four glioblastomas and one of two metastases
revealed obvious amplifications in at least one gene for
each tumor. Measurements of the peaks for each gene
were connected to create line graphs. The obvious peaks
representing high-level and some mid-level gene amplifi-
cations in the glioblastomas are shown in Figure 4.
Genes are listed along the x-axes according to amplicon
size within each kit (P171, 172 and 173). Easily recog-
nized amplifications occurred for EGFR, CDK4, MDM2,
CYP27B1, and PDGFRA in one or more GBMs, and also
for CCNE1 in one of the brain metastases (not shown)
using DNA from ultrasonic surgical aspirations. Com-
parable amplifications for the same genes were also
detected in corresponding FFPE specimens (not shown).
Results for non-amplified genes in the tumors and in
normal brain (assayed concurrently) constitute the base-
lines of graphs in Figure 4. The EGFR data obtained with
MLPA is included in Table 3 along with FISH data.
Following NB normalization to generate CN ratios,
Bland-Altman analysis (n= 889, derived from 127 data
points/tumor x 7) found that data in ultrasonic surgical
aspiration assays corresponded to data from FFPE assays
for the same tumor within 1.96 SD limits, except for
some of the amplifications that exceeded CN ratios of 15
(log value = 1.176). A normal CN ratio of 1 corresponds
to a log value of 0 (Figure 5A). Correlation coefficients
for comparisons ranged from 0.71 to 0.99 in studies of
each tumor according to the kits used. Consistency was
high with the exception of LCM2 that showed slightly
less correspondence, as seen in Figure 5B. The n’s were
42, 42, and 43 for P171, P172, and P173 kits, respect-
ively, in each tumor.
Normalized CN ratios for specific genes in glioblastomas,
including those with high-level amplifications (CN ratio≥
6.0) and those with no alterations (all CN ratios ≥0.75 and
≤1.5), are shown in Figure 6 (A & B, respectively). Both the
ultrasonic surgical aspiration and corresponding FFPE
results from the same tumors are shown. The only high-
level gene amplification in the brain metastases was EVI1
(7.02 CN ratio) in LCM2 FFPE but it was not amplified in
the corresponding aspiration specimen. The metastases,
LCM1 and LCM2, had 2 and 6 mid-level gene amplifica-
tions, respectively. The ependymoma (EP1) only had 1
mid-level gene amplification. Among the 10 genes with no
alterations in any of the GBMs, including replicates of all
probe sets for a specific gene, there were 9 genes that were
also unaltered in EP1, and 9 and 6 genes that were un-
altered in LCM1 and LCM2, respectively. Totals of all
deviations (<0.75 or ≥2.0 in CN ratios) from normal values
in ultrasonic aspiration and FFPE specimens are shown in
Table 4. Alterations in CN were more frequent in FFPE
than in ultrasonic aspiration specimens, 85% and 49% of
total changes, respectively. However, FFPE did not com-
pletely encompass all of the changes. Restriction of some
Figure 2 Morphology of the cavitronic ultrasonic surgical aspiration (CUSA) and FFPE specimens from several tumors. Specimens for
GBM1, GBM2, GBM4, and LCM1 are shown in the first, second, third, and fourth rows, respectively. The original magnification for the first column
(panels A, D, G, and J) was at 100X and the others were at 400X. Comparable morphology of the ultrasonic aspiration and FFPE specimens from
each tumor is noted in the high power views shown in the last 2 columns. Cellular pleomorphism and mitoses were prominent. Characteristic
regions of necrosis and vascular proliferation were also found in the FFPE sections of the GBMs (not shown). Several clinicopathologic features
are listed in Table 2. The portions of the CUSA specimens shown had been processed in the same manner as the FFPE specimens. Hematoxylin
and eosin stain. Magnifications bars represent 100 micrometers.
Table 2 Selected clinicopathologic features of the brain
tumors in this study




Pre Op Post Op
GBM1 50 yr M 80.8 19.1 46.5 ± 6.4 61 %
GBM2 81 yr M 51.4 0.0 19.5 ± 2.1 55 %
GBM3 52 yr F 124.0 96.1 10 ± 2.8 38 %
GBM4 44 yr M 35.6 0.0 18.5 ± 2.1 Not tested
LCM1 55 yr M 19.0 0.0 51.5 ± 9.2 Not tested
LCM2 61 yr M 6.5 0.0 64.5 ± 5.0 Not tested
EP1 73 yr M 20.6 1.38 0 10 %
The volumes of tumor were provided as estimates by the neurosurgeon.
HPF = high power field (400X).
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from the same tumor is consistent with tumor
heterogeneity.
Discussion
Overview of tumor genomics
Brain tumors are known for harbouring genetic ab-
normalities. Tumor genomes are being evaluated to
varying extents by FISH, array comparative genomic
hybridization (aCGH), single nucleotide polymorphism
(SNP) arrays, specific mutation detection with various
PCR methods, methylation studies, targeted sequen-
cing of selected genes, and whole genome sequencing.
Therapies are planned accordingly in some institu-
tions. Ideally, molecular testing for potential treat-
ment targets occurs at the time of diagnosis and
Figure 3 FISH results for EGFR are shown. A. Relative frequencies of EGFR/CEP 7 signals (number of cells in intervals/total cells counted
multiplied by 100) in FFPE sections of glioblastomas are shown on the y-axis in distributions of signal ratios. Data is skewed to the right due to
cells that harboured very high numbers of EGFR signals in each tumor, especially GBM3 and GBM4. Intervals of values for signal ratios along the
x-axis are equal except for the last two which are arbitrarily larger (in parentheses). B. Representative tumor cells show EGFR (orange/red) and CEP
7 (green) signals. Nuclei were stained blue with DAPI. All tumors had FFPE sections analyzed and a few also had CUSA specimens analyzed
successfully. Others had interference from proteinaceous debris. High power photographs were printed in large format and then digitized.
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treatment alterations.
Amplified oncogenes in tumor fluids
This study demonstrates that high-level amplified
oncogenes can be quickly detected by inexpensive
multiplex, PCR-based studies of cellular fluids using
standard molecular laboratory equipment and techni-
ques. Fluids with significant tumor cellularity offer
the opportunity to retrieve fresh tumor DNA in
abundant amounts. Advantages in testing the DNA of
tumor cells in fluids rather than FFPE tissue sections,
include avoidance of exposure to formalin, heat, and
organic solvents, and enrichment for tumor viapelleting, filters, and various other methods, such as
those developed for isolating tumor cells from blood.
Tumor cells in fluids not needed diagnostically con-
stitute as a potential source of DNA for molecular
assays. This study demonstrated detection of ampli-
fied oncogenes despite concerns regarding ultrasonic,
mechanical, and osmotic distortions and mixing of
the tumor cells with saline and blood. Endothelial
cells were the predominant type of non-tumor cell
present but these do not exceed what was originally
present in the tumor parenchyma. A tendency for
short sections blood vessels to remain intact and
sediment differently from tumor cells was noted but
was not investigated.





DNA ratios (normalized CN)
Average of 2 MLPA






GBM1 7.3 7.2 8.8 ± 0.2 21.1 ± 2.0
GBM2 8.6 9.3 22.5 ± 7.9 19.3 ± 7.2
GBM3 10.3 9.0 10.5 ± 3.8 33.1 ± 17.2
GBM4 11.1 11.6 19.5 ± 9.3 26.7 ± 6.5
LCM1 1.0 1.0 1.2 ± 0.5 1.2 ± 0.4
LCM2 1.1 1.0 2.3 ± 0.9 2.3 ± 1.4
EP1 1.0 1.0 1.7 ± 0.7 2.9 ± 2.6
Although amplification of EGFR seen in individual cells of GBMs varied greatly
and MLPA provided collective results of numerous cells, both techniques
demonstrated corresponding large elevations in copy number for this
oncogene in GBMs. Polysomy may have accounted for low-level amplifications
found with MLPA in LCM2 and EP1. Median ratios were derived from the
distributions of signal ratios in individual cells. EGFR= Epidermal Growth Factor
Receptor. CEP 7= Centromere of chromosome 7, FISH= Fluorescence in situ
hybridization. SD = Standard deviation. CUSA=Cavitronic ultrasonic surgical
aspiration. FFPE = Formalin-fixed, paraffin embedded tissue.
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It is proposed that oncogenes can be adaptively amplified
in tumor cells to increase key gene products while circum-
venting promoters and other traditional methods of gene
regulation [7,8]. Tumor cells are already well known for
developing resistance to chemotherapy by being permis-
sive to amplification of a gene that encodes a key protein
that aids drug metabolism [7]. Although genetic instability
of brain tumors may account for some genes being ampli-
fied by chance, amplification of multiple oncogenes
involved in a similar function, such as cellular proliferation
or resistance to apoptosis, suggests an adaptive response.
Co-amplification of multiple oncogenes that provoke re-
dundant malignant behavior or adaptation to cancer treat-
ments strengthens the rationale for planning multi-agent
therapies based on identification of amplified oncogenes
with multiplex techniques.
Although co-amplifications of several oncogenes have
been reported in glioblastomas, the lack of predictable pat-
terns in individual tumors indicates that each tumor needs
to be tested. Despite a tendency for genes in close proxim-
ity to be amplified together in tumor genomes, the span of
amplifications in these regions is variable and frequently
interrupted. Amplified expanses of chromosomes include
both “driver” and “passenger” or “bystander” genes in re-
gard to their effects on tumor behaviour. The benefits of
amplified “driver” genes could underlie retention of ampli-
fied chromosomal regions in malignant tumor clones.
Specific oncogenes amplified in glioblastomas
Several oncogenes are commonly amplified in brain
tumors. Amplification of EGFR or one of its variants,EGFRvIII, whose encoded protein is constitutively active,
is well-known to occur in primary glioblastomas. Ampli-
fication of EGFR has also been found in anaplastic astro-
cytomas [9]. Gains of EGFR occurred in 70% of 40
glioblastomas in one study with high levels of gene amp-
lification occurring as double minutes in 42% of the
cases. Lower levels of EGFR amplification occurred as
insertions of extra gene copies distributed along
chromosome 7 [10]. In a previous MLPA study of 104
glioblastomas, 74 (71%) had additional copies of EGFR
[11]. Although high levels of EGFR most likely underlie
some malignant adaptations in glioblastomas, only small
subsets of patients have responded to therapies targeted
to EGFR in clinical trials [12-15]. Five moderate to high-
level amplified genes in glioblastomas identified in this
study, EGFR, PDGFRA, CDK4, MDM2 and CYP27B1,
have also been previously reported, sometimes with co-
amplification [16-20]. Although proximity of the loca-
tions for CDK4, CYP27B1 and MDM2 at 12q14,
12q13.1-q13.3 and 12q14.3-q15, respectively, contributes
to co-amplification, this cannot be assumed to occur for
all three genes in individual tumors. In 20 glioblastomas
that harbored at least one of these amplifications, only 7
had amplification of all 3 genes [20]. In another study
when 5 glioblastomas contained amplification of either
MDM2 or CDK4, both genes were amplified in only 3
[18]. In another study, among the 5 glioblastomas that
contained amplification of either CDK4 or MDM2, only
one tumor had both amplified [17]. In a survey of 456
glioblastomas, 13.4% had amplifications of CDK4 but
only 9.2% had amplification of MDM2 [16]. In our study,
2 of 4 glioblastomas had co-amplifications of CDK4 and
CYP27B1 and only one also had amplification of
MDM2. Amplification of EGFR was present in all four
glioblastomas.
Amplifications of oncogenes in other brain tumors
Brain metastases from lung primaries in this study also
contained amplified oncogenes suggesting that genomic
analysis of metastases will detect amplified genes to
serve as treatment targets, such as CCNE1 that encodes
cyclin E1 [21,22]. Additional analyses of brain metastases
are indicated to identify the full range of oncogenes that
can be amplified. Interestingly, in a previous MLPA
study of non-typical meningiomas, 19 oncogenes were
found to have amplifications in two or more invasive/
atypical/anaplastic (mostly Grade II) meningiomas (total
of 15) and the sums of copy numbers were inversely cor-
related with patient age [5]. Some of those genes were
among the high-level amplified genes detected here but
none of the amplifications in the non-typical meningi-
omas were in the high-level range. In this study, sums of
CN ratios normalized with NB for the same 19 genes
were higher in all 4 glioblastomas and in 1 of the 2
Figure 4 Multiple gene amplifications detected with MLPA in GBM1-4 shown as line graphs of peak heights. MLPA results for genes in
tumors were compared with non-neoplastic (or normal) brain DNA. Heights of peaks reflected amounts of genes, or their CN. Mid to high-level
gene amplifications were obvious by visual inspection of peak heights (mm) for at least one gene in each glioblastoma. These are labelled and
also asterisks indicate these genes along the x-axes. Line graphs connecting the peak heights are colored according to the legends. Tumor and
normal brain (NB) were tested concurrently.
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previously (not shown).
Implications of amplified oncogenes
As products of amplified genes become treatment tar-
gets, combinations of specific inhibitors and monoclonal
antibodies will need to be tailored for individual patients
according to amplifications found in the tumor DNA.
Additionally, there is a tendency for amplified oncogenes
to undergo mutations. Therefore, testing each braintumor for oncogene amplifications would be useful for
detecting key molecular treatment targets.
Methods for assessments of oncogenes
With multiplex PCR methodology, rapid assessment of a
relatively large group of oncogenes can be obtained using
routine molecular laboratory techniques and equipment.
In comparison to FISH assays, numerous genes can be
tested simultaneously with comparisons to multiple non-
amplified genes, whereas the number of FISH targets is
Figure 5 Comparisons between cavitronic ultrasonic surgical aspiration (CUSA) and FFPE specimens for all normalized CN ratios. A.
Bland-Altman analysis demonstrated that normalized CN ratios ([tumor DNA]/[NB DNA]) obtained from either source of DNA corresponded
significantly (within 1.96 SD limits, dotted lines) for oncogene amplifications up to at least 15-fold (log value of 1.18). The logarithmic scale was
used on the x-axis to separate ratio values for the majority of the data points as much as possible. Note that a normal CN ratio of 1 is equivalent
to a log value of 0. The CN ratios for all genes tested with each kit (multiple probes) in all tumors were included, n= 889. B. The CN ratios derived
from the two sources of DNA exhibited strong correlations in each tumor with results from each kit shown separately. Assays using the MLPA
kits, P171, P172, and P173, had n’s equal to 42, 42 and 43, respectively.
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offer the advantage of detecting centromere duplication as
a surrogate of chromosomal duplication so that low levels
of EGFR amplification attributed to polysomy could be
predicted. In comparison to the specificity of other PCR-
based assays, amplification occurred with MLPA only if
the probes hybridized to the gene targets in pairs (probe
sets) and then underwent enzymatic ligation based on per-
fect sequence correspondence at their junctions to the
tumor DNA. Also, the use of only one-fourth of the reac-
tion volume for PCR in MLPA further reduced the
chances of non-specific carryover of PCR amplicons from
previous reactions. However, our study did not compareMLPA with other multiplex PCR techniques. Quantitative
real-time PCR using multiwell plates is among other rapid
molecular techniques to consider for testing multiple
oncogenes simultaneously at low cost.
The validity of MLPA has been supported by other
techniques. Detection of gene amplification (ERBB2 or
Her- 2/neu) with fluorescent and chromogenic in situ
hybridization has closely correlated with MLPA results
[23,24]. Results of EGFR amplification with MLPA have
been comparable to detection of increased protein and
RNA expression using immunohistochemistry and non-
MLPA PCR, respectively [10]. In this study, FISH con-
firmed MLPA results for the presence or absence of mid
Figure 6 Individual CN ratios of selected genes in CUSA and FFPE specimens from all four glioblastomas. A. The CN ratio values for
genes with high-level amplifications (CN ratios≥ 6.0) are shown for individual glioblastomas as indicated along the x-axis. Each gene, except for
MDM2, was tested with two probe sets. B. In contrast, the CN ratio values are shown for individual genes that were unaltered within all four
glioblastomas. These CN ratios remained in the normal range for all replicates and probe sets in all assays on both types of glioblastoma
specimens. Note the marked difference between the ranges of y-axes for A and B. The CN ratios were calculated according to [tumor DNA] / [NB
DNA] with averages in 95 % confidence intervals (bars) shown here.
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Table 4 Copy number changes in formalin-fixed, paraffin-embedded (FFPE) and cavitronic ultrasonic surgical
aspiration (CUSA) specimen DNA
Tumors Genes with normalized CN ratios≥ 2.0
(gains in copy number)
Genes with normalized CN ratios< 0.75
(losses in copy number)








GBM1 18 17 7 11 1 16 12 6 10 4
GBM2 10 10 5 5 0 21 17 9 12 4
GBM3 13 13 7 6 0 21 18 8 13 3
GBM4 10 8 8 2 2 15 13 7 8 2
LCM1 7 7 5 2 0 15 12 11 4 3
LCM2 15 13 5 10 2 32 22 18 14 10
EP1 7 7 3 4 0 16 15 6 10 1
Totals 80 75 40 40 5 136 109 65 71 27
GBM1-4 had increased CN ratios for 22 genes (AURKA, BCL2A1, BCL6, BIRC1,2,4, BRAF, CDK4,6, CYP27B1, EGFR, ERBB4, ESR1, EVI1, GNAS, GSTP1, MDM2, NRAS,
PDGFRA, PIK3CA, RNF139, & SERPINB9) and decreased CN ratios for 35 (AKT1, BCAR3, BCAS1, BCL2, BCL2L13, BCLG, BIRC5, BRMS1, CCND1, CCNE1, CDK4, CENPF, EMS,
FGF4, FGFR1, FLJ20517, GSTP1, IGF1R, IGFBP2, IRS2, JAK2, MDM4, MYBL2, MYC, MYCL1, MYCN, NFKBIE, NTRK1, PDGFRB, PIK3C2B, PTK2, PTP4A3, PTPN1, TERT, &TOM1L2).
LCM1-2 had increased CN ratios for 16 genes that overlapped with those for GBM1-4 plus CCNE1, MET, PPM1D, and PSMB4, and decreased CN ratios were found
for thirty six genes that overlapped with those listed for GBM1-4 plus BCL2L1, BIRC3, CYP27B1, MMP7, NTRK2, NTRK3, PDGFRA, RELA, & SERPINB2. EP1 had increased
CN ratios for genes among those for GBM1-4 and decreased CN ratios for those for GBM1-4 or LCM1-2 plus CCND3, HMGA1, & MOS.
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http://www.diagnosticpathology.org/content/7/1/66and high-level EGFR amplification. Correlations were
not quantified due to the potential for FISH signals to
merge in tandem repeats or as aggregates of double min-
utes and also the heterogeneity of results in individual
tumor cells.
The cost of kit reagents in a single MLPA assay is less
than $15. Although testing a tumor and normal brain
DNA with two replicates each in three reactions to en-
compass probes for 79 genes increases the cost, testing
multiple tumors with the same control DNA could be
performed. Also, the number of genes to be screened
could be reduced so that only 1 kit would be needed. Al-
though high-level gene amplification results were
obtained from the ultrasonic aspirations within a few
days and the content of tumor DNA was plentiful, it
should be noted that the FFPE assays demonstrated
higher sensitivity in detection of low to mid-level gene
amplifications. Therefore, ideally both types of speci-
mens would be tested if detection of all levels of onco-
gene amplifications is desired. Multiplex detection of
high-level amplifications using both types of samples
strengthens confidence in the results at a relatively low
cost and helps to negate concerns about tumor
heterogeneity.
Although DNA from patients’ blood cells has been
used as normal controls when searching for somatic
genetic alterations in tumors, quantifying high-level
amplified oncogenes pose a problem when using blood
samples. Very low numbers of circulating tumor cells
with high-level amplifications or their free DNA in the
blood could bias analyses. Thus this study used normal
brain DNA that was comparable to normal values
expected with MLPA that were provided by themanufacturer. Pooled DNA from multiple normal
donors should be considered for future studies. Based
on this pilot study, automation of steps in the MLPA
procedure and subsequent data analysis are future goals
so that this type of assay can be streamlined, validated,
and used clinically.
Conclusions
In summary, multiplex detection of high-level amplifica-
tions among oncogenes was successful in ultrasonic sur-
gical aspiration DNA obtained from malignant brain
tumors when compared with FFPE from the same
tumors. The results indicate that morphologic evaluation
of ultrasonic surgical aspirations to confirm tumor cell
content and retrieval of DNA would aid molecular test-
ing of brain tumors for oncogene amplifications. Many
of the oncogenes with copy number gains encode pro-
teins that are potential therapeutic targets. Therefore
rapid identification of high-level gene amplifications
could stratify patients to clinical trials and treatment
plans shortly after surgical resections of brain tumors.
Although ultrasonic surgical aspiration specimens are
less sensitive than FFPE in detecting low to mid-level
amplifications, the bulk of the tumor is present in the
aspirations, they are fresh and homogenously mixed, and
high-level amplifications can be detected in them. Abun-
dant tumor DNA harvested from cellular fluids could
also be used for targeted sequencing of amplified onco-
genes to detect activating mutations.
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